Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Thaler

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Case Reports in Oncology|March 28, 2024
Functional Precision Medicine Successfully Guides Therapeutic Regimen of 'Cancer of Unknown Primary' Later Classified as Triple-Negative Breast Cancer: A Case ReportLarissa Ruhe, Sonja Heibl, Manfred Czompo, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerClaus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, et al.
BMC Cancer|October 2, 2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyJosef Thaler, Meinolf Karthaus, Laurent Mineur, et al.
Drugs in R&D|July 14, 2019
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus PanitumumabClaus-Henning Köhne, Meinolf Karthaus, Laurent Mineur, et al.
Frontiers in Oncology|May 31, 2024
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysisGudrun Piringer, Florian Ponholzer, Josef Thaler, et al.
Cancers|March 13, 2024
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 TrialYawen Dong, Jonas Santol, Birgit Gruenberger, et al.
Leukemia & Lymphoma|August 31, 2017
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1Sonja Burgstaller, Reinhard Stauder, Thomas Kuehr, et al.
International Journal of Oncology|September 10, 2003
Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimensWolfgang Hilbe, Margit Dlaska, Stephan Dirnhofer, et al.
Hematological Oncology|August 7, 2020
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1Sonja Heibl, Veronika Buxhofer-Ausch, Stefan Schmidt, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Case Reports in Oncology|March 28, 2024
Functional Precision Medicine Successfully Guides Therapeutic Regimen of 'Cancer of Unknown Primary' Later Classified as Triple-Negative Breast Cancer: A Case ReportLarissa Ruhe, Sonja Heibl, Manfred Czompo, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerClaus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, et al.
BMC Cancer|October 2, 2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyJosef Thaler, Meinolf Karthaus, Laurent Mineur, et al.
Drugs in R&D|July 14, 2019
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus PanitumumabClaus-Henning Köhne, Meinolf Karthaus, Laurent Mineur, et al.
Frontiers in Oncology|May 31, 2024
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysisGudrun Piringer, Florian Ponholzer, Josef Thaler, et al.
Cancers|March 13, 2024
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 TrialYawen Dong, Jonas Santol, Birgit Gruenberger, et al.
Leukemia & Lymphoma|August 31, 2017
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1Sonja Burgstaller, Reinhard Stauder, Thomas Kuehr, et al.
International Journal of Oncology|September 10, 2003
Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimensWolfgang Hilbe, Margit Dlaska, Stephan Dirnhofer, et al.
Hematological Oncology|August 7, 2020
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1Sonja Heibl, Veronika Buxhofer-Ausch, Stefan Schmidt, et al.
Pageof 8